Cargando…

519. Risk Factor Analysis for Hospital Admission Following Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Monoclonal Antibody Treatment

BACKGROUND: The FDA has issued emergency use authorization (EUA) for neutralizing monoclonal antibodies (mAb) for the treatment of mild-moderate coronavirus disease 2019 (COVID-19) in patients who are at high risk of disease progression. The EUA allows for COVID-19 mAb infusion to occur up to 10 day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abusalem, Lana, Wood, Cole, Crescencio, Juan Carlos Rico, Dare, Ryan K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644710/ http://dx.doi.org/10.1093/ofid/ofab466.718

Ejemplares similares

46. Antimicrobial Stewardship’s Selective Antibiotic Suppression Does Not Lead to Adverse Outcomes in Neutropenic Patients with Gram-Negative Bacteremia
por: Witt, Anna, et al.
Publicado: (2020)

553. Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Treatment with Monoclonal Antibody Therapy (MAT) in the Outpatient Setting
por: Nichols, Courtney, et al.
Publicado: (2021)

519. Immune responses and COVID-19 severity
por: salvatore, mirella, et al.
Publicado: (2020)

535. Comparison of Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Monoclonal Antibody Therapy (MAT) with Bamlamivimab or Casirivimab-Imdevimab
por: Nichols, Courtney, et al.
Publicado: (2021)

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
por: Chatterjee, Suparna, et al.
Publicado: (2022)

519 Weekend Admission for Patients with Hidradenitis Suppurativa Have Better Outcomes than Weekday Admission
por: Atayeva, Rena, et al.
Publicado: (2023)

554. Clinical Impact of Monoclonal Antibody Therapy with SARS-CoV-2 Infection
por: Mann, Inderjit, et al.
Publicado: (2021)

1327. Human Rhinovirus Infection in Multiple Myeloma Patients: Effect on Morbidity and Mortality
por: Hasan, Lana, et al.
Publicado: (2021)

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
por: Abusalem, Mohammed, et al.
Publicado: (2023)

Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure
por: Hunter, Benton R., et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

513. Use of Antimicrobial Stewardship Program in Operationalizing Monoclonal Antibody Therapy in SARS-CoV-2 Infection
por: Abrantes-Figueiredo, Jessica, et al.
Publicado: (2021)

479. Real-world Evaluation of SARS-CoV-2 Monoclonal Antibodies in Solid Organ Transplant Recipients
por: Zeitler, Kristen, et al.
Publicado: (2021)

514. Anti-SARS-CoV-2 Monoclonal Antibodies for Early COVID-19: A Real World Experience
por: Belden, Katherine, et al.
Publicado: (2021)

532. Establishing a SARS-CoV-2 Monoclonal Antibody Infusion Clinic: Early Trends in Outcomes and Disparities
por: Hare, Allison J, et al.
Publicado: (2021)

Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2022)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

Pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska
por: Haan, Tracie J., et al.
Publicado: (2022)

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients
por: Piccicacco, Nicholas, et al.
Publicado: (2021)

Amelioration of joint inflammation by a PAR-2-specific monoclonal antibody
por: King, V, et al.
Publicado: (2005)

533. Protocol for and Efficacy of Monoclonal Antibody (mAb) Treatment of SARS-CoV-2 at a VA Medical Center
por: Nguyen, Phuong Khanh, et al.
Publicado: (2021)

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)

Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody Therapy
por: Jacobs, Jana L, et al.
Publicado: (2023)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens
por: de Souza, Matheus Oliveira, et al.
Publicado: (2022)

501. Serum IgG Antibody Testing Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers
por: Juskowich, Joy J, et al.
Publicado: (2020)

SUN-519 Hypokalemic Periodic Paralysis
por: Godfrey, Sean, et al.
Publicado: (2020)

367. Clinical Characteristics and Outcomes in Patients with Pneumonia secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
por: Nichols, Courtney, et al.
Publicado: (2020)

Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
por: Sivapalasingam, Sumathi, et al.
Publicado: (2021)

Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses
por: Kumar, Rinki, et al.
Publicado: (2021)

1790. Dethroning Vancomycin: A Multifaceted Stewardship Approach to Reduce Vancomycin in an Academic Medical Center
por: Lusardi, Katherine, et al.
Publicado: (2022)

Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies
por: Maghsood, Faezeh, et al.
Publicado: (2022)

Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia in Patients Treated With Anti-CD20 Monoclonal Antibodies
por: Furie, Nadav, et al.
Publicado: (2023)

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies
por: Qiu, Hongyu, et al.
Publicado: (2021)

P519: RISK STRATIFICATION BY NOMOGRAM SCORING SYSTEM OF NPM1-MUTATED CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIALEUKAEMIA BASED ON A MULTI-GENE PANEL
por: Zhao, Mingyue, et al.
Publicado: (2023)

Novel monoclonal antibodies against pathogenic Leptospira
por: de Matos, Bruno Moisés, et al.
Publicado: (2014)

P1098: OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE TREATMENT WITH ANTICD20 MONOCLONAL ANTIBODIES IN SARS-COV2 ERA: RESULTS FROM A MULTICENTER, RETROSPECTIVE- PROSPECTIVE ITALIAN STUDY.
por: Castellino, A., et al.
Publicado: (2022)

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Functionality of Monoclonal Antibody Therapy in SARS-CoV-2
por: Ali, Ruhma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_21s280r32c3a3m0tsqf44u2rus